<DOC>
	<DOCNO>NCT00009750</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy peripheral stem cell transplantation may effective treatment metastatic prostate cancer . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy plus chemotherapy follow peripheral stem cell transplantation treat patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Plus Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Patients With Metastatic Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y90 monoclonal antibody m170 administer paclitaxel cyclosporine follow autologous peripheral blood stem cell transplantation patient hormone-refractory metastatic prostate cancer . - Determine preliminary efficacy regimen patient . OUTLINE : This open-label , dose-escalation study yttrium Y 90 monoclonal antibody m170 ( Y90 MOAB m170 ) . Patients assign one four cohort . After first occurrence hematologic dose-limiting toxicity patient , subsequent patient receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin 4 day prior undergoing apheresis continue 6 million CD34+ cells/kg collect . After 2 patient cohort group experience hematologic dose-limiting toxicity , subsequent patient undergo autologous peripheral blood stem cell ( PBSC ) transplantation . - Cohort I : Patients receive unlabeled monoclonal antibody ( MOAB ) m170 IV 5 minute follow tracer dose indium In 111 monoclonal antibody m170 ( In111 MOAB m170 ) IV 5-10 minute day 0 unlabeled MOAB m170 IV follow Y90 MOAB m170 IV day 7 . Patients also receive oral cyclosporine every 12 hour day -3 25 . Patients may undergo autologous PBSC transplantation day 21 receive G-CSF SC daily begin day 21 continue blood count recover . - Cohort II : Patients receive treatment cohort I . Patients also receive paclitaxel IV 3 hour day 9 . - Cohort III IV : Patients receive treatment cohort I without In111 MOAB m170 . Patients also receive paclitaxel cohort II . Cohorts 3 6 patient receive escalate dos Y90 MOAB m170 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 2 6 patient experience dose-limiting toxicity . Patients follow monthly 3 month , every 3 month 1 year , every 6 month 1 year . PROJECTED ACCRUAL : A total 18-30 patient accrue study within 36 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm hormonerefractory metastatic prostate cancer Hormonal ablation ( surgical chemical ) least 3 month prior study HAMA titer negative Less 25 % bone marrow involvement metastatic prostate cancer PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,00/mm^3 Hemoglobin least 10.0 g/dL ( without transfusion ) No chronic transfusion requirement Hepatic : Bilirubin great 1.3 mg/dL AST great 1.5 time normal Renal : Creatinine le 1.5 mg/dL Cardiovascular : LVEF least 50 % MUGA No disseminate intravascular coagulation Pulmonary : FEV1 least 65 % predict FVC least 65 % predict Corrected DLCO least 60 % Other : Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior murine protein ( e.g. , ProstaScint ) Chemotherapy : At least 4 week since prior standard dose chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : At least 4 week since prior external beam radiotherapy No prior radiotherapy 25 % total skeleton Surgery : See Disease Characteristics Other : No concurrent oral anticoagulant ( low dose coumadin central line thrombosis prophylaxis allow ) No concurrent chronic transfusion</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2003</verification_date>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>